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http://dxObjective: To describe the use of extracorporeal membrane oxygenation (ECMO) in acute resuscitation after
cardiac arrest in pediatric patients with heart disease, with reference to patient selection and predictors of
outcome.
Methods: A retrospective medical record review was performed of all patients aged 21 years with heart
disease who had undergone ECMO for cardiopulmonary resuscitation (ECPR) at Texas Children’s Hospital
from January 2005 to December 2012. The most recent Pediatric Overall Performance Category score was
determined from the patients’ medical records.
Results: During the study period, 62 episodes of ECPR occurred in 59 patients, with 27 (46%) surviving to
hospital discharge and 25 (43%) alive at the most recent follow-up visit. The overall survival to discharge
for patients with myocardial failure (myocarditis, cardiomyopathy, or after transplantation) and structural heart
disease was similar (40% vs 50%, P ¼ .6). No patient with restrictive cardiomyopathy survived; 1 patient
(13%) in ECPR group after late cardiac graft failure survived to discharge. Survival to discharge was greater
for patients who were intubated (70%) at cardiac arrest (P ¼ .001). The presence of pre-existing acute kidney
injury at cardiac arrest (62%) was associated with greater mortality (P¼ .059). A Pediatric Overall Performance
Category score of2 (indicating good neurologic performance) was present in 68% of the survivors; 7 patients
(87%) with a score>2 had abnormal imaging findings (P ¼ .01).
Conclusions: ECPR was associated with modest survival in pediatric patients with heart disease; however, this
was associated in part with the underlying disease and pre-existing comorbidities, including the presence of
acute kidney injury. (J Thorac Cardiovasc Surg 2014;148:2367-72)E
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SExtracorporeal membrane oxygenation (ECMO) in the
setting of active cardiopulmonary resuscitation (ECPR)
has gained widespread acceptance in the resuscitation algo-
rithm for pediatric patients with heart disease.1 ECMO itself
is a highly specialized, low-volume therapy that has been
associated with significant morbidity and mortality and
consumes substantial resources. It has generally been
accepted that the subset of ECMO patients receiving
ECPR represents the greatest risk subgroup in terms of mor-
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The Journal of Thoracic and CarSupport Organization has reported the survival to hospital
discharge after ECPR in patients aged<18 years at around
40%, and, in many centers, ECPR now constitutes about
one half of all cardiac ECMO support.2
As the use of ECPR has continued to grow, it has come
under increasing scrutiny with respect to cost, indications,
patient selection, and patient outcomes. Lowry and col-
leagues3 recently showed that the hospital charges incurred
after ECPR were more than twice that of the propensity-
matched conventional CPR, with no overall difference in
survival from amulti-institutional outcomes database. The in-
dications for ECPR are broad, with the most prominent sub-
groups being children with structural heart disease (SHD)
and thosewithmyocardial failure (eg,myocarditis, cardiomy-
opathy, or failure of the transplanted heart).Whenconsidering
the outcomes after therapy as invasive as ECPR, one must
consider factors other than survival to discharge from the
ECMO center, the primary endpoint for the Extracorporeal
Life Support Organization registry. Longer term survival
and the associated burden of disease, in particular, neurodis-
ability, are important outcome measures in this high-risk
population. It is likely that patient selection will be vitally
important in making good use of this resource.
The purpose of the present study was to retrospectively
review our institutional experience with ECPR in pediatric
patients with heart disease in a mixed medical and surgicaldiovascular Surgery c Volume 148, Number 5 2367
Abbreviations and Acronyms
AKI ¼ acute kidney injury
CVICU ¼ cardiovascular intensive care unit
ECMO ¼ extracorporeal membrane oxygenation
ECPR ¼ extracorporeal cardiopulmonary
resuscitation
IQR ¼ interquartile range
POPC ¼ Pediatric Overall Performance Category
RIFLE ¼ risk, injury, failure, loss, and end-stage
renal function
SHD ¼ structural heart disease
TCAD ¼ transplant-related coronary artery disease
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Scardiovascular intensive care unit (CVICU). Our emphasis
was on the outcomes in terms of survival to discharge and
neurologic status at follow-up and on the patient factors
that might influence these outcomes.METHODS
The institutional review board of Baylor College of Medicine approved
the present study. We identified all CVICU patients at Texas Children’s
Hospital who had required ECPR from April 2005 to December 2012.
The start point of our review was selected because it marked the formal
introduction of an ECPR protocol in the CVICU, with the availability of
a plasmalyte-primed ECMO circuit at all times. ECPR was defined as
the initiation of ECMO support in the setting of active CPR. The present
review included patients who had had cardiac arrest outside the CVICU
(the inpatient floor, emergency department, catheterization laboratory)
who had undergone cannulation for ECMO and had received ongoing
care in the CVICU. The decision to initiate ECMOwasmade by the cardiac
surgeon, cardiac intensivist, and cardiologist, where possible, with the fam-
ily’s written or verbal consent to proceed.
Patients
All patients through the age of 21 years (pediatric age group as defined
by the American Academy of Pediatrics) with SHD or myocardial failure
who had received ECPR were included in the present review. We collected
demographic profiles for all the patients, the details of the underlying dis-
ease, the clinical parameters immediately before cardiac arrest, including
patient location, the use of mechanical ventilation, the use of inotropes,
renal function, and laboratory values, including lactate and pH. We used
the pediatric risk, injury, failure, loss, and end-stage renal function (RIFLE)
score to classify acute kidney injury (AKI) in patients according to the last
creatinine clearance measurement before cardiac arrest.4 The duration of
the cardiac arrest before establishing ECMO, the cannulation site,
ECMO duration, surgical procedures during support, major complications,
organ system failure, hospital stay length, and patient survival to discharge
were also recorded. For nonsurvivors, we documented the timing and cause
of death (including later mortality after initial hospital discharge).
Neurologic Assessment
For survivors, we recorded the results of the neurologic assessment at
the most recent follow-up point using the Pediatric Overall Performance
Category (POPC) score.5-7 The POPC score assesses cognitive
impairment and functional morbidity, including general adaptive or
physical limitations after critical illness or injury. It has a 6-point graded
scale from normal function (score, 1) to death (score, 6). A POPC score2368 The Journal of Thoracic and Cardiovascular Surof 2 indicates a good neurologic outcome consistent with mild disability
at most. A score>2 indicates a poor neurologic outcome, consistent with
moderate to severe disability.5,8 The source and point of assessment was
the documentation in our electronic medical records from the most
recent office visit with the pediatrician, cardiologist, occupational
therapist, or neurologist.
ECMO Support
Our in-house ECPR equipment throughout the period of review
included a centrifugal ECMO pump and a wet-primed circuit that was
available at all times. In the early part of our experience, we used a Bio-
medicus pump (Medtronic, Minneapolis, Minn) and Minimax oxygenator
(Medtronic). Since 2009, we have been using the HL20 console with the
Rotaflow pump (Maquet, Hirrlingen, Germany) and the pediatric or adult
Quadrox hollow-fiber oxygenator (Maquet). After the establishment of
ECMO, where possible, catecholamine medications were weaned, fol-
lowed by the initiation of vasodilators. Mechanical ventilation was initially
reduced to the ‘‘rest settings,’’ with total ventilatory pressures of 20/10, a
mandatory rate of 10 breaths/min, and an inspired oxygen fraction of
<0.4. A heparin infusion was begun at 10 to 20 U/kg/h and adjusted to
maintain an activated clotting time of 180 to 200 s, heparin (anti-Xa) level
of 0.4 to 0.7, and an antithrombin level>80%. Muscle relaxants were not
routinely used after stabilization on ECMO and regular sedation weaning
was performed to provide an opportunity to assess the neurologic status.
In younger infants, cranial ultrasound examinations were performed every
24 to 48 hours. Also, although we did not have a specific protocol relating
to computed tomography or the use of electroencephalography, these were
frequently performed to assist with the overall evaluation for brain injury.
The application of hypothermia for 24 to 48 hours after arrest was not
routine and was largely dependent on the treating clinician. Latterly, this
adjunctive therapywas used very infrequently. However, ECMOwas other-
wise used to control the patient’s body temperature at normothermia
(36.5C-37C). Renal replacement therapy (ultrafiltration or continuous
hemofiltration) was performed routinely in most patients for initial and
early fluid removal or to provide additional renal support in the presence
of more established AKI or renal failure.
Statistical Analysis
Continuous data are presented as the median values with the interquar-
tile range (IQR). The categorical data are expressed as the frequencies and
percentages. The data variables were compared between the survivors and
nonsurvivors. The continuous variables were compared using the Mann-
Whitney rank sum test. All dichotomous variables were assessed using
the Fisher exact test. Multivariate logistic regression analysis was used to
identify the factors independently associated with survival after ECPR.
All variables with a univariate regression level of significance of P<.1
were subsequently tested in a multivariable logistic regression model.
RESULTS
Patient Characteristics
During the period of review, 103 episodes of temporary
ECLS occurred in 99 patients, of which 62 (60.2%) were
ECPR in 59 patients (59.6%; 3 patients underwent a second
run of ECPR). The median age was 12.7 months (IQR,
1.2-91.5), and the median weight was 7.8 kg (IQR, 4-23).
Of the 59 patients, 32 (54%) had SHD and 27 had myocar-
dial failure.
Of the 32 patients with SHD, 30 had undergone surgery:
20 (66%) were within 30 days of surgery and 10 (33%)
were in the convalescent phase (>30 days after surgery).
The timing of ECPR in the group within 30 days of surgerygery c November 2014
TABLE 1. Patient characteristics
Variable All patients (n ¼ 59) Survivors (n ¼ 27) Nonsurvivors (n ¼ 32) P value
Median age (mo) 12.69 (1.2-91) 6.4 (1.3-84.7) 15.7 (1.2-92.9) .52
Median weight (kg) 7.8 (4-22.7) 6.8 (4.5-23) 9 (3.2-26) .95
Failure to thrive 17 (28) 5 (18.5) 12 (37.5) .12
Chromosomal anomaly 8 (13.5) 3 (11) 5 (15.6) .6
AKI (RIFLE-I, F) 37 (62) 13 (48) 24 (75) .03
Primary diagnosis
SHD, single ventricle 17 (28) 8 (29) 9 (28) .8
SHD, biventricular 15 (25) 8 (29) 7 (22) .49
Dilated cardiomyopathy 6 (10) 3 (12) 3 (9) .82
Restrictive cardiomyopathy 4 (6.7) 0 (0) 4 (12.5) .05
Myocarditis 7 (11.8) 6 (22) 1 (3) .02
Long QT syndrome 2 (3.3) 1 (3) 1 (3) .9
Post-transplant 8 (13.5) 1 (3) 7 (22) .04
Time of arrest (7 AM-7 PM) 46 (77) 22 (81) 24 (75) .24
Interval from arrest to ECMO (>30 min) 40 (67) 14 (52) 26 (76) .01
Median duration of ECMO (h) 76 (39-104) 72 (41-115) 81 (31-103) .5
Mechanical ventilation immediately before arrest 32 (54) 21 (77) 11 (34) <.01
Inotropes, 1 or none at arrest 18 (30) 10 (37) 8 (25) .3
Location of arrest (ICU) 36 (61) 18 (66) 18 (56) .4
Location of cannulation (ICU) 29 (49) 11 (40) 18 (56) .23
Site of cannulation (central) 34 (57) 20 (74) 14 (43) .02
pH before arrest (<7.2) 18 (30) 11 (40) 7 (21) .2
Lactate before arrest (>5) 28 (47) 14 (51) 14 (43) .5
Operative interventions on ECMO 20 (33) 11 (40) 9 (28) .3
Data presented as median (interquartile range) or n (%). AKI, Acute kidney injury; RIFLE, risk, injury, failure, loss, and end-stage renal function; I, injury; F, failure; SHD,
structural heart disease; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit.
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Swas 2.0 days (IQR, 1.75-9.0) after surgery. The specific
patient diagnosis for the postoperative patients was hypo-
plastic left heart syndrome in 6, pulmonary atresia with
an intact ventricular septum in 4, atrioventricular septal
defect in 4, double outlet right ventricle in 3, Shone’s com-
plex and variants in 3, transposition of the great arteries in 2,
pulmonary atresia with a ventricular septal defect in 2,
congenitally corrected transposition of the great arteries in
2, truncus arteriosus in 1, and tricuspid atresia in 1. The
cause of cardiac arrest included ventricular dysfunction in
10, pulmonary hypertension in 3, acute arrhythmia in 3,
and shunt compromise in 3. The exact cause of the cardiac
arrest was unknown in 11 patients. Two patients had unop-
erated SHD: one with pulmonary atresia and an intact ven-
tricular septum who had acute cardiac compromise in the
catheterization laboratory, and an older child with a late
diagnosis of a transitional atrioventricular septal defect
and acute pulmonary hypertension.
A total of 27 patients with myocardial failure (cardiomy-
opathy, arrhythmia, or myocarditis) underwent ECPR dur-
ing the study period (Table 1). Eight patients underwent
ECPR after orthotopic heart transplantation; the underlying
pathophysiology was transplant-related coronary artery dis-
ease (TCAD) in 5, acute rejection in 1, and late graft failure
in 2. In these patients, the median interval between trans-
plantation and ECPR was 6.0 years (IQR, 3.7-7.0).The Journal of Thoracic and CarThree patients underwent 2 runs of ECPR. The first pa-
tient presented first at 13 years with dilated cardiomyopa-
thy; after ECPR, he underwent transplantation and was
discharged. Six years later, he experienced cardiac arrest
secondary to TCAD and did not survive after ECPR owing
to a severe neurologic injury. The second patient was a
6-month-old infant who had presented with dilated cardio-
myopathy and required ECPR. One week after being
weaned from ECMO, the patient underwent a second run
of ECPR and was transitioned to a left ventricular assist de-
vice. The patient subsequently underwent transplantation
and was doing well at the latest follow-up point. The third
patient had had 2 runs of ECPR in the same admission for
compromise from TCAD 8 years after heart transplantation.
While awaiting a heart, he experienced a third event at
which point it was not thought appropriate to offer ECMO.
Hospital Outcomes
In the ECPR group, 35 (59.3%) survived to decannula-
tion and 27 (45.7%) survived to hospital discharge. A total
of 24 patients did not survive weaning from ECMO because
of multiorgan failure with or without cardiac recovery in 16
(50%) and severe neurologic injury leading to a withdrawal
of support in 8 (25%); 8 patients (25%) were weaned from
ECMO but died before discharge. The cause of death was
persistent heart failure due to TCAD in 4, restrictivediovascular Surgery c Volume 148, Number 5 2369
FIGURE 1. Outcomes for extracorporeal cardiopulmonary resuscitation in cardiac patients.OHT, Orthotopic heart transplantation; VAD, ventricular assist
device; ECPR, extracorporeal cardiopulmonary resuscitation.
TABLE 2. Neurologic status at follow-up for ECPR survivors
Variable
POPC  2
(n ¼ 17)
POPC>2
(n ¼ 8) P value
Interval from arrest to ECMO
(>30 min)
6 (35) 6 (75) .06
Abnormal imaging findings 5 (29) 7 (87) .01
Data presented as n (%). POPC, Pediatric Overall Performance Category; ECMO,
extracorporeal membrane oxygenation.
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Scardiomyopathy in 1, graft dysfunction in 1, shunt occlu-
sion in 1, and diffuse intravascular thrombosis in 1. The me-
dian duration between decannulation and death was 49 days
(IQR, 30-63).
Six patients were transitioned to a long-term ventricular
assist device using complete cardiopulmonary bypass
with the intention of bridging to heart transplantation (2
with primary dilated cardiomyopathy, 1 with TCAD, 1
with myocardial failure secondary to Kawasaki’s disease,
1 with ventricular failure late after Fontan operation, and
1 with Shone’s complex with muscular ventricular septal
defects and pulmonary hypertension who had several failed
attempts at closing the defects at outside institutions). Five
patients underwent heart transplantation and were dis-
charged home, of whom 3 were alive at the last follow-up
point (Figure 1).
Factors Affecting Hospital Survival
In the patients with SHD, survival was similar in those
with a functionally univentricular circulation and those
with a biventricular circulation. A diagnosis of restrictive
cardiomyopathy (no survivors) and ECPR late after cardiac
transplantation were associated with nonsurvival. In
contrast, a diagnosis of myocarditis, mechanical ventilation
immediately before cardiac arrest, the absence of pre-
existing renal dysfunction (RIFLE failure or injury), a
shorter CPR duration, and central cannulation were all asso-
ciated with improved survival (Table 1). On multivariate
analysis, improved hospital survival was associated with
mechanical ventilation at cardiac arrest (OR, 8.5; 95%
CI, 2.48-35.6; P ¼ .0013) and the absence of pre-existing
AKI (OR, 3.5; 95% CI, 0.975-14.6; P ¼ .059).
Outcomes at Follow-up
The median follow-up period was 19 months (IQR, 8-59)
from hospital discharge, at which point, 25 patients had2370 The Journal of Thoracic and Cardiovascular Sursurvived (43% of the original cohort). Two deaths occurred
after discharge: 1 in the patient with TCAD who had died
after the second run of ECPR and the other secondary to
an aspiration event 3 months after bidirectional Glenn. In
terms of neurologic performance, 17 survivors (68%) had
a POPC score of 2, indicating no neurologic injury or
only mild injury. Of the 8 patients with a POPC score
> 2, 6 (75%) had had a CPR duration of>30 minutes
compared with 6 (35%) with a POPC score of 2
(P ¼ .06). The neurologic sequelae included global devel-
opmental delay in 3 patients (2 of whom were technology
dependent at home), hemiparesis with speech delay in 1,
seizures with mild delay in milestones in 3, and documented
learning deficit in 2 patients (although 1 patient had a POPC
score of 2 with the learning disability). Twenty-three survi-
vors had undergone brain imaging studies (ultrasonography
in 1, computed tomography in 14, and magnetic resonance
imaging in 8), with abnormal results for 12 (55%). A hyp-
oxic injury was present in 5 (22%), infarct with or without
hemorrhage in 5 (22%), isolated microcephaly in 1 (4%),
and isolated hemorrhage in 1 (4%). Of the patients with a
POPC score> 2, 7 (87%) had abnormal imaging results
(P ¼ .01; Table 2).
DISCUSSION
In the present review, we have shown survival to hospital
discharge after ECPR in a mixed population of childrengery c November 2014
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Swith medical and surgical heart disease of 46%, with sub-
sequent survival to the most recent follow-up point of
43%. We have also demonstrated significant variability in
survival according to the nature of the underlying heart dis-
ease, with ECPR in the setting of restrictive cardiomyopa-
thy or cardiac graft failure associated with very poor
outcomes. We have shown for the first time that pre-
existing renal dysfunction according to the pediatric RIFLE
classification is associated with mortality.
The overall survival to hospital discharge was similar to
the published data relating to ECPR and to cardiac
ECMO in general.9,10 In the present cohort, a diagnosis of
SHD (single ventricle or biventricular physiology),
myocarditis, and dilated cardiomyopathy were associated
with the most favorable long-term outcomes. However,
the presence of TCAD, graft failure, or restrictive cardio-
myopathy was not. The published data have suggested
that the overall outcomes for patients with TCAD while
awaiting transplantation have been poor, with 50% of pa-
tients experiencing graft loss or death within 2 years of
the diagnosis.11 Moreover, the risk of a poor outcome sec-
ondary to cardiac compromise or severe systemic infection
after left ventricular assist device implantation as a bridge to
repeat transplantation in this population is known to be very
high,12 limiting the exit strategy for these patients. We had
no survivors to discharge in the patients with restrictive car-
diomyopathy. This diagnosis is known to be associated with
an overall mortality rate of 50% within 2 years of the diag-
nosis,13,14 with an increased incidence of sudden cardiac
death15 and relatively high mortality during mechanical cir-
culatory support compared with that of other subgroups.16
The complex circulatory physiology in this group could
lead to inadequate systemic and myocardial oxygen deliv-
ery during CPR in these patients, contributing to the overall
poor outcomes.
Survival after ECPR can be influenced by pre-existing pa-
tient factors at cardiac arrest.17 Although AKI at cardiac ar-
rest has been associated with poor outcomes after ECMO,18
we have, for the first time, applied the pediatric RIFLE score
to this population. We found a trend toward clinical signif-
icance in our patients, with increased survival in the group
with no injury and risk, as determined by the RIFLE cate-
gories. These more subtle indicators of early or preclinical
AKI might reflect a more prolonged state of impaired car-
diac output that, when superimposed with an acute loss of
cardiac output, reduces the chances of organ system recov-
ery. Another precardiac arrest factor that conferred a signif-
icant protective effect on patient survival was already being
intubated at the cardiac arrest. This is likely to be associated
with a number of favorable factors, including the ability to
provide full CPR without delay, the immediate presence of
experienced ICU personnel, secure vascular access, and car-
diovascular monitoring, with all immediately available at
cardiac arrest. The duration of CPR before the initiationThe Journal of Thoracic and Carof ECLS has been a point of contention.17,19-21 Although
our data did demonstrate a difference on univariate
analysis, no difference was found after multivariate
regression, likely reflection of our small sample size.
The overall outcomes of high-risk interventions should
no longer simply be defined according to survival but
should ideally include indicators of the quality of survival
and long-term morbidity and burden. Although we did not
have access to detailed neurodevelopmental or neurologic
assessments of our patients, we did apply a widely used
score (the POPC) to our cohort; 68% of our survivors
had minimal or no neurologic disability at the last
follow-up visit. This was comparable to the findings for
other large cohorts, with severe neurologic disability vary-
ing from 9% to 40%.7,17,21-25 Six patients (75%) with a
POPC score>2 had had a CPR duration of>30 minutes,
which was associated with a trend between the duration
of CPR and the neurologic outcomes. Nine of our
survivors had a significant neurologic impairment,
varying from technology dependence (tracheostomy
and gastrostomy tube) to a learning disability. Also,
87% of our patients with moderate to severe disability
had abnormal neuroimaging findings. This indicates
that neuroimaging in the setting of a formalized
neurodevelopment assessment can be included as an
integral part of long-term care.
The present study had several limitations. First, the retro-
spective nature of the study precluded the development of
any predictive data points. These results were from a
single-center experience and a heterogeneous population,
limiting the generalizability of these results and the predic-
tive power. Finally, the neurologic assessment for our survi-
vors was determined by a review of the medical records
from their last office visits rather than formal evaluations
We did not have a baseline POPC score at discharge or
before ECPR to make a comparison. We recognize these
crucial limitations and are currently in the process of incor-
porating formal neurodevelopmental assessments for all our
ECLS patients.CONCLUSIONS
ECMO can be used as an adjunctive tool in resuscitation
after cardiac arrest in children with heart disease. Important
patient factors, including diagnostic group and the presence
of pre-existing AKI, were identified as potential predictors
for outcome after ECPR. These factors can be used not only
to guide patient selection for ECPR, but also ideally to
guide preemptive decision making regarding the institution
of mechanical support.
We would like to thank Miss Bonnie Hendricks in helping
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